44 / 52
ANALES
OFTALMOLÓGICOS
Tomo VII • Vol. I • N˚1-2-3 · 2015 • Santiago - Chile
13. Mitchell P., Bandello F., Schmidt-Erfurth
U., Lang GE., Massin P., Schlingemann RO.,
Sutter F, Simader C, Burian G, Gerstner O,
Weichselberger A; RESTORE study group.
The RESTORE study: ranibizumab
monotherapy or combined with laser versus
laser monotherapy for diabetic macular
edema. Ophthalmology. 2011 Apr;118(4):615-
25.
14. Mitchell P, Massin P, Bressler S, Coon
CD, Petrillo J, Ferreira A, Bressler NM.
Three-year patient-reported visual function
outcomes in diabetic macular edema
managed withranibizumab: the RESTORE
extension study. Curr Med Res Opin. 2015
Nov;31(11):1967-75.
15. Diabetic Retinopathy Clinical Research
Network, “Expanded 2-year follow-up of
Ranibizumab plus prompt or deferred laser or
Triamcinolone plus prompt laser for diabetic
macular edema,” Ophthalmology, vol. 118, no.
4, pp. 609–614, 2011.
16. Do D., Schmidt-Erfurth U., Gonzalez V., and Da
Vinci Study Group The DA VINCI Study: Phase 2
Primary Results of VEGF Trap-Eye in Patients
with Diabetic Macular Edema. Ophthalmology
2011;118:1819–1826
17. Korobelnik J., Do D., Schmidt-Erfurth
U., Boyer S. and VIVID/VISTA study group
Intravitreal Aflibercept for Diabetic Macular
Edema. Ophthalmology 2014;121:2247-2254
18. Wells J., Glassman A, Ayala A., Jampol L.,
Bressler N., Bressler S., et al for the Diabetic
Retinopathy Clinical Research Network.
Aflibercept, Bevacizumab, or Ranibizumab
for Diabetic Macular Edema Ophthalmology
2016;- :1- 9 2016 by the American Academy of
Ophthalmology.
19. Gillies M., Lim L., Campain A., et al. A
randomized clinical trial of intravitreal
bevacizumab versus intravitreal
dexamethasone for diabetic macular edema:
the BEVORDEX study. Ophthalmology. 2014
Dec;121(12):2473-81
20. VISION Clinical Trial Study Group. Year 2
efficacy results of 2 randomized controlled
clinical trials of pegaptanib for neovascular
age-related macular degeneration.
Ophthamology 2006 Sep; 113(9): 1-25
21. Comparison of Age-related Macular
Degeneration Treatments Trials (CATT)
Research Group* Ranibizumab and
Bevacizumab for Treatment of Neovascular
Age-Related Macular Degeneration Two-Year
Results Ophthamology 2012; Jul;119(7):1388-
98
22. Chakravarthy U., Harding S., Downes S., Lotery
A., Reeves B., and IVAN study investigators
Alternative treatments to inhibit VEGF in age-
related choroidal neovascularisation: 2-year
findings of the IVAN randomised controlled
trial. Lancet 2013; Oct 12; 382(9900): 1258-
1267
23. D. M. Brown, M. Michels, P. K. Kaiser, J. S.
Heier, J. P. Sy, and T. Ianchulev, “Ranibizumab
versus verteporfin photodynamic therapy
for neovascular age-related macular
degeneration: two year results of the ANCHOR
Study,” Ophthalmology, vol. 116, no.1, pp.
57.e5–65.e5, 2009.
24. Rosenfeld p., Brown D., Heier J., Boyer D., et
al for the MARINA Study Group. Ranibizumab
for Neovascular Age-Related Macular
Degeneration N Engl J Med 2006; 355:1419-
1431
25. Abraham P., Yue H., Wilson L. Randomized,
double-masked, sham-controlled trial of
ranibizumab for neovascular age-related
macular degeneration: PIER study year 2. Am
J Ophthalmol 2010 Sept; 150 (39): 315-324
26. Schmidth-Erfurth U., Eldem B., Guymer R., et
al for EXCITE study group. Efficacy and safety
of monthly versus quarterly ranibizumab
treatment in neovascular age-related
macular degeneration: the EXCITE study.
Ophthalmology 2011 MAy; 118(5): 831-9
27. Busbee B., Ho A., Brown D., et al for the
HARBOR study group Twelve-Month Efficacy
and Safety of 0.5 mg or 2.0 mg Ranibizumab
in Patients with Subfoveal Neovascular Age-
Related Macular Degeneration Ophthalmology
2013 May;120(5):1046-56
28. Heier J., Brown D., Chong V., et al for VIEW
1 and VIEW 2 study group. Intravitreal
Aflibercept (VEGF Trap-Eye) in Wet Age-
related Macular Degeneration Ophthalmology
2012;119:2537–2548
29. Tah V., Orlans H., Hyer J., et al Anti-VEGF
Therapy and the Retina: An Update Journal
of Ophthalmology Volume 2015, Article ID
627674, 13 pages
30. Klein et al. Trans Am Ophthalmol Soc 2000; 98:
133-141
31. Campochiaro P., Heier J., Feiner L. et al
for BRAVO Investigators Study Group.
Ranibizumab for macular edema following
branch retinal vein occlusion: six-month
primary end point results of a phase III study
Ophthalmology. 2010 Jun;117(6):1102-1112
32. Brown D., Campochiaro P., Singh R. et al
for CRUISE Investigators Study Group.
Ranibizumab for macular edema following